Epilepsy

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 30, 2020.

In the largest study of its kind to date, researchers at Indiana University attempt to elucidate previously inconclusive literature on antiseizure drugs, autism, and ADHD.

The professor of neurology at the NYU Langone Grossman School of Medicine gave her reaction to the data she and colleagues published on neurologic disorders in patients with COVID-19.

Patients treated surgically reported better outcomes, including reduced AED use, higher rates of survival, and fewer epilepsy-related ED visits, hospitalizations, and outpatient visits.

The Medical Director of The Neuroscience Institute at UW Medicine Valley Medical Center discussed the landscape of therapy for tonic-clonic seizures and how lacosamide might fit into the paradigm.

The professor of neurology at the NYU Langone Grossman School of Medicine discussed a recent study she and colleagues conducted on new neurological disorders in patients with COVID-19.

The FDA told Xeris that it could advance diazepam directly into a phase 3 registration study for both pediatric and adult patients with epilepsy after reviewing phase 1b results.

The educational webinar series will feature 7 of the world leaders in Dravet Syndrome and will conclude on November 16 with a presentation from Ian Miller, MD.

The section chief of pediatric neurology at Nationwide Children’s Hospital discusses some of the challenges that patients with Lennox-Gastaut syndrome and their caregivers face.

Here's what is coming soon to NeurologyLive.

The lead investigator of the study and assistant professor of neurology at University of Colorado School of Medicine, Jacob Pellinen, MD, spoke to the importance of identifying nonmotor seizures.

A number of poster presentations suggest that fenfluramine (Fintepla; Zogenix) offers a high percentage of patients with Dravet syndrome an opportunity to reduce monthly convulsive seizure frequency

Despite the continual epilepsy treatment landscape growth, there are only a few if any approved therapies for rare developmental and epileptic encephalopathies.

Neurology News Network for the week ending October 24, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 23, 2020.

The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, explained when and how prescription management changed amid the COVID-19 pandemic.

For those with nonmotor seizures at onset who developed seizures with motor involvement later, the median number of days to diagnosis from motor symptom onset was only 13 days, compared to 616 days for the overall nonmotor group.

Here's what is coming soon to NeurologyLive.

The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, shared his thoughts on how technology has affected patient care and the patient-physician dynamic during the COVID-19 pandemic.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 16, 2020.

Patients with neurologic disorders were more often older, male, white, hypertensive, diabetic, intubated, and had higher sequential organ failure assessment scores.

Topiramate oral solution is Eton’s third neurology product candidate submitted to the FDA, this time seeking 3 indications.

Sucheta M. Joshi, MD, MS, FAES, FAAP, and Nicholas Beimer, MD, discussed the reasons why EpiTRAQ may influence earlier discussions with patients prior to the epilepsy transition process.

Here's what is coming soon to NeurologyLive.

The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, discussed whether certain epilepsy populations were affected greater by the COVID-19 pandemic.